Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Infect Dis. 2012 Jan 1;54(1):96-104. doi: 10.1093/cid/cir774. Epub 2011 Dec 7.

Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.

Author information

  • 1Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA. aabutt@pitt.edu

Abstract

Recent approval of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) offers a major advance in the management of HCV infection. These DAAs, boceprevir and telaprevir, when given with pegylated interferon alfa (Peg-IFN) and ribavirin (RBV), result in a much higher sustained virologic response rate compared with Peg-IFN and RBV. The DAA-containing regimens are approved for HCV genotype 1 infection in HCV treatment-naive and HCV treatment-experienced patients. In this review, we present an overview of pharmacology, efficacy, adverse events, and emergence of resistance-associated variants with the use of these agents. As with all drugs, especially newly approved drugs, clinicians must consult the package insert for detailed prescribing information, list of all reported adverse events, contraindications, and drug interactions.

PMID:
22156853
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk